BAM
MYGN icon

Belpointe Asset Management’s Myriad Genetics MYGN Stock Holding History

Belpointe Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-35
Closed -$813 – 2316
2023
Q1 		$813 Buy
+35
New +$711 ﹤0.01% 3507

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Belpointe Asset Management's MYGN Position: Q2 2023 in Review

Belpointe Asset Management sold out of Myriad Genetics (MYGN) in Q2 2023, closing a stake of 35 shares — an estimated $813 sold.

Belpointe Asset Management first reported a position in MYGN in Q1 2023 and held it in 1 quarter. The position peaked at $813 in Q1 2023. 188 funds tracked by Wall St. Rank hold MYGN as of Q2 2023.

  • Belpointe Asset Management reported no remaining Myriad Genetics position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 35 Myriad Genetics shares in Q2 2023, an estimated $813.
  • Belpointe Asset Management first reported a position in Myriad Genetics in Q1 2023 and held it in 1 quarter.
  • Belpointe Asset Management's Myriad Genetics position peaked at $813 in Q1 2023.
  • 188 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.